Casey C. Lynch


Casey Lynch is the CEO, Co-founder, and Chair of Cortexyme, a clinical stage biopharmaceutical company pioneering a novel approach for treatment of Alzheimer’s and other degenerative disorders. Prior to co-founding Cortexyme, she co-founded and led various companies and organizations in the biotechnology industry including Aspira Biosystems, Inc. and NeuroInsights, LLC. Casey also co-founded the Neurotechnology Industry Organization and served as a board member until 2018. Earlier in her career, she oversaw toxicology screening and evaluated new product opportunities at Centaur Pharmaceuticals, including multiple sclerosis, arthritis, and uveitis and conducted preclinical testing for Alzheimer’s disease treatment at the Wadsworth Medical Center. She holds a B.S. in Neuroscience from the University of California, Los Angeles, and M.S. in Neuroscience from the University of California, San Francisco.

Year appointed: 2014

Register for this year’s Action for Impact Summit happening on September 25, 2024!